CHRISTINA BOORD: Open Payments
NPI 1336815091 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,182 in 48 payments from 11 companies in 2025. Trend: 2023 $455 · 2024 $771 · 2025 $2,182
Long term medical supply or device loan: $1,147Food & beverage: $935Education: $99
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $1,205 |
| Daiichi Sankyo Inc. | 11 | $297 |
| Gilead Sciences, Inc. | 9 | $229 |
| SEAGEN INC. | 1 | $99 |
| TerSera Therapeutics LLC | 3 | $84 |
| Merck Sharp & Dohme LLC | 3 | $83 |
| PFIZER INC. | 2 | $52 |
| Genentech USA, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $36 |
| Lilly USA, LLC | 1 | $31 |
Products named: KISQALI, Enhertu, Trodelvy, Zoladex, KEYTRUDA, FRUZAQLA, VERZENIO, Itovebi.
Industry payments across MD — which companies pay providers there.
